Compare Stocks → Charles Payne Demystifies Options (From Unstoppable Prosperity) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:AMARNASDAQ:CNATNASDAQ:KMPHNASDAQ:MYOS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMARAmarillo Biosciences$0.60$0.05▼$1.97$25.24M-0.0618,253 shs6,100 shsCNATConatus Pharmaceuticals$0.20$1.00$0.23▼$1.07$6.63M1.841.28 million shs6 shsKMPHZevra Therapeutics$5.51$4.00▼$6.92$200.47M2.16189,500 shs64,100 shsMYOSMYOS RENS Technology$3.35$0.74▼$3.85$16.70M1.081.68 million shsN/AThese 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMARAmarillo Biosciences0.00%0.00%0.00%0.00%0.00%CNATConatus Pharmaceuticals0.00%0.00%-60.00%-41.18%-76.34%KMPHZevra Therapeutics0.00%0.00%0.00%0.00%0.00%MYOSMYOS RENS Technology0.00%0.00%0.00%-54.79%+661.11%The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside himMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMARAmarillo BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ACNATConatus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AKMPHZevra TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMYOSMYOS RENS TechnologyN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMARAmarillo BiosciencesN/AN/AN/AN/ACNATConatus PharmaceuticalsN/AN/AN/AN/AKMPHZevra TherapeuticsN/AN/AN/AN/AMYOSMYOS RENS TechnologyN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMARAmarillo Biosciences$20K0.00N/AN/A($0.03) per share0.00CNATConatus Pharmaceuticals$21.72M0.31N/AN/A$0.53 per share0.38KMPHZevra Therapeutics$10.72M0.00N/A23.28$3.63 per share0.00MYOSMYOS RENS Technology$1.03M0.00N/AN/A$0.13 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMARAmarillo Biosciences-$1.45MN/A0.00N/AN/A-41,453.98%N/A-574.29%N/ACNATConatus Pharmaceuticals-$11.39MN/AN/A∞N/A-52.42%-48.22%-39.32%N/AKMPHZevra Therapeutics-$8.56MN/A0.00N/AN/A-328.56%-16.12%-14.17%N/AMYOSMYOS RENS Technology-$4.26MN/AN/AN/AN/A-277.82%-166.68%-104.95%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMARAmarillo BiosciencesN/AN/AN/AN/AN/ACNATConatus PharmaceuticalsN/AN/AN/AN/AN/AKMPHZevra TherapeuticsN/AN/AN/AN/AN/AMYOSMYOS RENS TechnologyN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMARAmarillo BiosciencesN/A0.030.07CNATConatus PharmaceuticalsN/A16.2816.28KMPHZevra Therapeutics0.1410.1010.10MYOSMYOS RENS Technology0.113.781.94OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMARAmarillo BiosciencesN/ACNATConatus Pharmaceuticals15.20%KMPHZevra Therapeutics19.39%MYOSMYOS RENS Technology4.97%Insider OwnershipCompanyInsider OwnershipAMARAmarillo Biosciences34.35%CNATConatus Pharmaceuticals11.30%KMPHZevra Therapeutics1.10%MYOSMYOS RENS Technology45.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAMARAmarillo Biosciences242.07 millionN/ANot OptionableCNATConatus Pharmaceuticals3033.17 millionN/ANot OptionableKMPHZevra Therapeutics2234.51 million34.13 millionOptionableMYOSMYOS RENS Technology1512.19 millionN/ANot OptionableKMPH, CNAT, MYOS, and AMAR HeadlinesSourceHeadlineRen Zhengfei says US government 'underestimates' Huaweibbc.com - December 23 at 1:17 PMPioneer announces The Ren as Business Partner of the Yearrichlandsource.com - November 20 at 1:50 PMShenqiang Renbuffalo.edu - October 4 at 3:32 PMAnthony M. Newman to Lead REN-ISAC Cybersecurity Centercampustechnology.com - August 27 at 9:26 PMCarbon-based quantum technologysciencedaily.com - August 19 at 4:05 PMBio-active Peptides Market Size 2023-2031 Industrial Trends by Absolute Reports | with [93 Pages]marketwatch.com - May 11 at 1:13 AMLatest "Bio-active Peptides Market" Size Forecast 2023-2031: New Challenges, Drivers, and Restraintsmarketwatch.com - May 8 at 9:06 PMBio-active Peptides Market Size Dynamics 2023-2029marketwatch.com - April 13 at 3:09 PMRenQ Finance (RENQ) raises $5 million, makes some serious buzz with its all in one DeFi platformcointelegraph.com - April 6 at 1:03 PMGlobal Bio-active Peptides Market: Future Extrapolations and Emerging Updates for 2023-2027marketwatch.com - March 21 at 9:47 AMBio-active Protein Market Size 2023 Research Report by Industrial Growth Analysis and Forecast till 2027marketwatch.com - March 13 at 10:33 AMCan Huawei thrive despite American sanctions?economist.com - October 29 at 10:12 AMBio-active Peptides Market Size, Share, 2022 Global Trends, Development Status, Opportunities, Competitive Landscape and Growth by Forecast 2028marketwatch.com - September 28 at 9:57 AMBio-Active Protein Market Is Likely to Experience a Strong Growth During 2022-2028 with Top Countries Datamarketwatch.com - August 4 at 1:49 AMRenaissance Festival tickets go on sale Friday, Aug. 5independenttribune.com - August 1 at 9:38 AMRensair raises $7m to establish clean air as a human rightwfmz.com - May 10 at 9:43 AMBioactive Protein Market Latest Analysis Report 2022: Global Industry Size, Share, Production, Growth Drivers and Strategic Outlook 2026wicz.com - January 12 at 2:06 PMBioactive Peptide Market to See Booming Growth 2021-2028 | Archer Daniels Midland Company, Seagarden AS, Phermpep Co. Ltd., Arlak Biotech Pvt. Ltd.chipdesignmag.com - November 1 at 10:13 PMICYMI: Everything you need to know about the iPhone 13yahoo.com - September 26 at 10:38 PMMYOS RENS Technology Inc. Common Stock (MYOS)nasdaq.com - July 29 at 10:47 PMMedia Sentiment Over TimeCompany DescriptionsAmarillo BiosciencesOTCMKTS:AMARAmarillo Biosciences, Inc., a healthcare company, engages in the discovery and development of pharmaceutical and biotech products in the United States and Asia. The company operates in three divisions: Pharmaceutical, Medical, and Consumer. The Pharmaceutical division offers low-dose non-injectable interferon (IFN) for the treatment of neoplastic, viral, and fibrotic diseases. The Medical division focuses on medical devices and developing technology to treat metabolism related diseases, such as Type 1 and Type 2 diabetes. The Consumer division provides a range of nutraceutical and food supplement products that utilize a liposomal delivery system. It owns four issued patents related to the low-dose oral delivery of interferon; one patent is for a product promoting oral health; and three patents are associated with treatment of metabolic disorders. The company was incorporated in 1984 and is based in Amarillo, Texas.Conatus PharmaceuticalsNASDAQ:CNATConatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company is also developing CTS-2090, an orally active inhibitor of caspase 1, which is in preclinical development stage for treating chronic diseases involving inflammasome pathways. The company has a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California.Zevra TherapeuticsNASDAQ:KMPHKemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.MYOS RENS TechnologyNASDAQ:MYOSMedAvail Holdings, Inc. is a technology-enabled pharmacy company. It provides turnkey in-clinic pharmacy services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations, to Medicare clinics. The firm helps patients to optimize drug adherence, resulting in better health outcomes. The company is headquartered in Mississauga, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.